

PFIZER INC  
Form 8-K  
April 07, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report: April 7, 2005  
Date of earliest event reported: April 7, 2005

**PFIZER INC.**

(Exact name of registrant as specified in its charter)

|   |  |  |
|---|--|--|
| <b>Delaware</b><br>(State or other Jurisdiction of<br>incorporation)                                    | <b>1-3619</b><br>(Commission File<br>Number) | <b>13-5315170</b><br>(I.R.S. Employer Identification<br>No.) |
| <b>235 East 42nd Street</b><br><b>New York, New York</b><br>(Address of principal<br>executive offices) |  | <b>10017</b><br>(Zip Code)                                   |

Registrant's telephone number, including area code:  
(212) 573-2323

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events

Edgar Filing: PFIZER INC - Form 8-K

On April 7, 2005, Pfizer Inc. issued a press release concerning new Food and Drug Administration (FDA) labeling for Celebrex and all other non-steroidal, anti-inflammatory drugs and concerning its agreement to suspend sales of Bextra pending further discussions with the FDA. A copy of the press release is included as Exhibit 99 to this report and is incorporated herein by reference.

Item 9.01 Financial  
Statements and Exhibits

(c) Exhibits

Exhibit 99                      Press Release of Pfizer Inc. dated April 7, 2005

**SIGNATURE**

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran  
Margaret M. Foran  
Title: Vice President-Corporate  
Governance and Secretary

Dated: April 7, 2005

**EXHIBIT INDEX**

| Exhibit No. | Description                                       |
|-------------|---|
| 99          | Press Release of Pfizer Inc. dated April 7, 2005. |